Tuesday, 17 April 2018

Glenmark Pharmaceuticals Share Gained More Than A Percent After The Drug Maker

Glenmark Pharmaceuticals share gained more than a percent after the drug maker announced the initiation of a Phase 2b clinical trial of GBR 830, a novel, investigational treatment for moderate-to-severe atopic dermatitis.

The trial's primary endpoint will assess the efficacy of GBR 830, compared to placebo. Secondary and exploratory trial endpoints include additional measures of efficacy, safety and pharmacodynamics. Trial enrollment is expected to begin in June 2018, it said.

For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory

No comments:

Post a Comment